ARHGAP–RhoA signaling provokes homotypic adhesion-triggered cell death of metastasized diffuse-type gastric cancer

Genetic alteration of Rho GTPase-activating proteins (ARHGAP) and GTPase RhoA is a hallmark of diffuse-type gastric cancer and elucidating its biological significance is critical to comprehensively understanding this malignancy. Here, we report that gene fusions of ARHGAP6/ARHGAP26 are frequent gene...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncogene 2022-10, Vol.41 (43), p.4779-4794
Hauptverfasser: Komatsu, Masayuki, Ichikawa, Hitoshi, Chiwaki, Fumiko, Sakamoto, Hiromi, Komatsuzaki, Rie, Asaumi, Makoto, Tsunoyama, Kazuhisa, Fukagawa, Takeo, Matsushita, Hiromichi, Boku, Narikazu, Matsusaki, Keisuke, Takeshita, Fumitaka, Yoshida, Teruhiko, Sasaki, Hiroki
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Genetic alteration of Rho GTPase-activating proteins (ARHGAP) and GTPase RhoA is a hallmark of diffuse-type gastric cancer and elucidating its biological significance is critical to comprehensively understanding this malignancy. Here, we report that gene fusions of ARHGAP6/ARHGAP26 are frequent genetic events in peritoneally-metastasized gastric and pancreatic cancer. From the malignant ascites of patients, we established gastric cancer cell lines that spontaneously gain hotspot RHOA mutations or four different ARHGAP6/ARHGAP26 fusions. These alterations critically downregulate RhoA–ROCK–MLC2 signaling, which elicits cell death. Omics and functional analyses revealed that the downstream signaling initiates actin stress fibers and reinforces intercellular junctions via several types of catenin. E-cadherin-centered homotypic adhesion followed by lysosomal membrane permeabilization is a pivotal mechanism in cell death. These findings support the tumor-suppressive nature of ARHGAP–RhoA signaling and might indicate a new avenue of drug discovery against this refractory cancer.
ISSN:0950-9232
1476-5594
DOI:10.1038/s41388-022-02469-6